Quarterly Cash & Current Investments rose 3.78% to $2.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 billion through Dec 2025, up 3.78% year-over-year, with the annual reading at $2.0 billion for FY2025, 3.78% up from the prior year.
Cash & Current Investments hit $2.0 billion in Q4 2025 for CRISPR Therapeutics AG, up from $1.9 billion in the prior quarter.
In the past five years, Cash & Current Investments ranged from a high of $2.6 billion in Q2 2021 to a low of $1.7 billion in Q4 2023.
Historically, Cash & Current Investments has averaged $2.0 billion across 5 years, with a median of $1.9 billion in 2024.
Biggest five-year swings in Cash & Current Investments: surged 174.0% in 2021 and later dropped 23.7% in 2022.
Year by year, Cash & Current Investments stood at $2.4 billion in 2021, then fell by 23.7% to $1.8 billion in 2022, then decreased by 6.7% to $1.7 billion in 2023, then increased by 12.41% to $1.9 billion in 2024, then rose by 3.78% to $2.0 billion in 2025.
Business Quant data shows Cash & Current Investments for CRSP at $2.0 billion in Q4 2025, $1.9 billion in Q3 2025, and $1.7 billion in Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value